SML0992
Bromosporine
≥98% (HPLC)
Synonym(s):
N-[6-(3-Methanesulfonamido-4-methylphenyl)-3-methyl-[1,2,4]triazolo[4,3-b]pyridazin-8-yl]carbamate
Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C17H20N6O4S
CAS Number:
Molecular Weight:
404.44
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
51111800
MDL number:
Product Name
Bromosporine, ≥98% (HPLC)
InChI
1S/C17H20N6O4S/c1-5-27-17(24)18-15-9-14(21-23-11(3)19-20-16(15)23)12-7-6-10(2)13(8-12)22-28(4,25)26/h6-9,22H,5H2,1-4H3,(H,18,24)
SMILES string
CC(C(NS(C)(=O)=O)=C1)=CC=C1C2=NN3C(C(NC(OCC)=O)=C2)=NN=C3C
InChI key
UYBRROMMFMPJAN-UHFFFAOYSA-N
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 20 mg/mL, clear
storage temp.
2-8°C
Quality Level
Related Categories
Biochem/physiol Actions
Bromodomains (BRDs) are protein-interaction modules that "read" ε-N-lysine acetylation motifs, such as those found in the N-terminal tails of histones. BRDs have been identified in chromatin-modifying enzymes (such as histone acetyltransferases (HATs)) as well as in transcription factors that regulate genes for cell cycle progression, signal transduction, apoptosis, and inflammation. Proteins containing bromodomains have been implicated in various diseases, such as cancers, inflammatory diseases and neurological diseases. Bromosporine is a broad spectrum BRD inhibitor. In HeLa cells, bromosporine accelerates FRAP recovery of BRD4 and CREBBP at 1μM. For full characterization details, please visit the Bromosporine probe summary on the Structural Genomics Consortium (SGC) website.
To learn about other SGC chemical probes for epigenetic targets, visit sigma.com/sgc
To learn about other SGC chemical probes for epigenetic targets, visit sigma.com/sgc
Bromosporine is an inhibitor for bromodomains.
Features and Benefits
Bromosporine is an epigenetic chemical probe available through a partnership with the Structural Genomics Consortium (SGC). To learn more and view other SGC epigenetic probes, visit sigma.com/SGC.
This compound is a featured product for Gene Regulation research. Click here to discover more featured Gene Regulation products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Berkley E Gryder et al.
Cancer discovery, 7(8), 884-899 (2017-04-28)
Alveolar rhabdomyosarcoma is a life-threatening myogenic cancer of children and adolescent young adults, driven primarily by the chimeric transcription factor PAX3-FOXO1. The mechanisms by which PAX3-FOXO1 dysregulates chromatin are unknown. We find PAX3-FOXO1 reprograms the
Ming Jang Chua et al.
International journal for parasitology. Drugs and drug resistance, 8(2), 189-193 (2018-04-10)
Bromodomain-containing proteins (BDPs) are involved in the regulation of eukaryotic gene expression. Compounds that bind and/or inhibit BDPs are of interest as tools to better understand epigenetic regulation, and as possible drug leads for different diseases, including malaria. In this
Hanyu Pan et al.
Oncotarget, 8(55), 94104-94116 (2017-12-08)
The long-lived latent HIV-1 reservoir is the major barrier for complete cure of Acquired Immune Deficiency Syndrome (AIDS). Here we report that a novel bromodomain and extraterminal domain (BET) inhibitor bromosporine which can broadly target BETs, is able to potently
Flore Mietton et al.
Nature communications, 8, 15482-15482 (2017-05-19)
Invasive fungal infections cause significant morbidity and mortality among immunocompromised individuals, posing an urgent need for new antifungal therapeutic strategies. Here we investigate a chromatin-interacting module, the bromodomain (BD) from the BET family of proteins, as a potential antifungal target
Alexander N Phillipou et al.
SLAS discovery : advancing life sciences R & D, 25(2), 163-175 (2019-12-26)
Malfunctions in the basic epigenetic mechanisms such as histone modifications, DNA methylation, and chromatin remodeling are implicated in a number of cancers and immunological and neurodegenerative conditions. Within GlaxoSmithKline (GSK) we have utilized a number of variations of the NanoBRET
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service